Cargando…

Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study

Background: Investigational and marketed drugs for the treatment of multiple myeloma (MM) are associated with a range of characteristics and uncertainties regarding long term side-effects and efficacy. This raises questions about what matters most to patients living with this disease. This study aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janssens, Rosanne, Lang, Tamika, Vallejo, Ana, Galinsky, Jayne, Plate, Ananda, Morgan, Kate, Cabezudo, Elena, Silvennoinen, Raija, Coriu, Daniel, Badelita, Sorina, Irimia, Ruxandra, Anttonen, Minna, Manninen, Riikka-Leena, Schoefs, Elise, Vandebroek, Martina, Vanhellemont, Anneleen, Delforge, Michel, Stevens, Hilde, Simoens, Steven, Huys, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289885/ https://www.ncbi.nlm.nih.gov/pubmed/34295912 http://dx.doi.org/10.3389/fmed.2021.686165

Ejemplares similares

What matters most to patients with multiple myeloma? A Pan-European patient preference study
por: Janssens, Rosanne, et al.
Publicado: (2022)

Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma
por: Irimia, Ruxandra, et al.
Publicado: (2023)

Muscle involvement with pseudohypertrophy in systemic light chain amyloidosis: Case report
por: Draghici, Mirela, et al.
Publicado: (2021)

Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature
por: Adam, Robert Daniel, et al.
Publicado: (2021)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population
por: Pauwels, Kim, et al.
Publicado: (2019)

Clinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian population
por: Jercan, Andreea, et al.
Publicado: (2020)

Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study
por: Moldovianu, Ana-Maria, et al.
Publicado: (2023)

Quantitative SPECT/CT Parameters in the Assessment of Transthyretin Cardiac Amyloidosis—A New Dimension of Molecular Imaging
por: Gherghe, Mirela, et al.
Publicado: (2023)

The simultaneous occurrence of multiple myeloma and JAK2 positive myeloproliferative neoplasms - Report on two cases
por: Badelita, S, et al.
Publicado: (2015)

Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
por: Morel, T., et al.
Publicado: (2016)

R&D Costs of New Medicines: A Landscape Analysis
por: Simoens, Steven, et al.
Publicado: (2021)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

How to balance valuable innovation with affordable access to medicines in Belgium?
por: Simoens, Steven, et al.
Publicado: (2022)

Opportunities and Challenges of Web-Based and Remotely Administered Surveys for Patient Preference Studies in a Vulnerable Population
por: Oliveri, Serena, et al.
Publicado: (2021)

Multinational democracies /
Publicado: (2001)

Multinational corporations
Publicado: (1990)

The multinational corporation
por: Liebenau, Jonathan
Publicado: (1984)

Multinational Telecommunications
por: Collective
Publicado: (1977)

Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice
por: Janssens, Rosanne, et al.
Publicado: (2018)

Key Determinants of Health-Related Quality of Life Among Advanced Lung Cancer Patients: A Qualitative Study in Belgium and Italy
por: Janssens, Rosanne, et al.
Publicado: (2021)

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
por: Jantunen, Esa, et al.
Publicado: (2023)

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?
por: Pauwels, Kim, et al.
Publicado: (2014)

Insights into European Drug Shortages: A Survey of Hospital Pharmacists
por: Pauwels, Kim, et al.
Publicado: (2015)

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
por: Pauwels, Kim, et al.
Publicado: (2016)

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
por: Abdallah, Khadidja, et al.
Publicado: (2021)

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021)

Carnitine Intake and Serum Levels Associate Positively with Postnatal Growth and Brain Size at Term in Very Preterm Infants
por: Manninen, Suvi, et al.
Publicado: (2022)

Erosive tooth wear and use of psychoactive substances among Finnish prisoners
por: Vainionpää, Raija, et al.
Publicado: (2019)

Dental Fear and Dental Health and Attendance among Finnish Male Prisoners
por: Vainionpää, Raija, et al.
Publicado: (2019)

What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study
por: Schoefs, Elise, et al.
Publicado: (2022)

Multinational business finance /
por: Eiteman, David K.
Publicado: (2001)

Multinational business finance /
por: Eiteman, David K.
Publicado: (1998)

Multinational business finance /
por: Eiteman, David K.
Publicado: (1992)

The New Mission for Multinationals
por: Santos, José
Publicado: (2015)

Toward a European definition for a drug shortage: a qualitative study
por: De Weerdt, Elfi, et al.
Publicado: (2015)

Time Investment in Drug Supply Problems by Flemish Community Pharmacies
por: De Weerdt, Elfi, et al.
Publicado: (2017)

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
por: Dutta, Binita, et al.
Publicado: (2019)

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
por: Barbier, Liese, et al.
Publicado: (2020)

European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_50afjo7m5n3p2vgeire08hgo52